Bayer likes all the brands it got from Merck, Coppertone and Dr. Scholl’s included

Carly Helfand Should Bayer sell some of the consumer brands it's buying from Merck in a $ 14 billion deal? Analysts say a few of them–Coppertone sun products, for instance–don't ...

Novartis hopes new COPD study data will draw patients from Glaxo’s Advair

Carly Helfand Novartis' generic of Advair in Europe is already a thorn in GlaxoSmithKline's side when it comes to sales of the declining blockbuster. Now, it says, another of ...

Novartis backs away from once-ambitious RNAi research

Tracy Staton Novartis is shuttering a large part of its once-ambitious RNAi research effort in Boston, FierceBiotech has learned. FiercePharma News

Sage snags $38M from A-list VCs to bankroll its seizure drugs

Damian Garde Cambridge, MA's Sage Therapeutics has hauled in a $ 38 million Series C, convincing a who's-who of biotech investors to pitch in as it pushes forward with a portfolio ...

Merck lays off its simian staff as the industry moves away from chimp research

Damian Garde Merck has joined the growing list of entities pulling the plug on chimpanzee research, folding to activist pressure and dismissing its primate subjects once and for all. FierceBiotech ...

New data positions Astellas prostate cancer med Xtandi to grab market share from J&J’s Zytiga

Tracy Staton Some new data on the prostate cancer drug Xtandi promises to heat up competition with Johnson & Johnson's Zytiga. Medivation and its partner Astellas Pharma unveiled ...

Lilly buys back a migraine therapy from Arteaus Therapeutics

Emily Mullin Eli Lilly has struck a deal with Arteaus Therapeutics to acquire the Cambridge, MA-based company's migraine therapy being studied in a Phase II clinical trial. FierceBiotech ...

Billionaire backs new program for a pioneering Alzheimer’s vaccine from AC Immune

John Carroll German billionaire Dietmar Hopp is adding to his multimillion-dollar wager on AC Immune, the Swiss biotech that is playing a key role in some high-profile Alzheimer's ...

Sanofi is allowing open access from Jan. 1 on out

Carly Helfand Following in the footsteps of Big Pharma counterparts like GlaxoSmithKline, Sanofi says it will provide data, documents and reports on studies used to support U.S. and ...

Teva Unveils New Pipeline Assets from the NTE Program

mia.burns  Teva unveils new pipeline assets from the NTE program of 2013 in the 2nd Teva R&D In-Focus Webinar – December 4th @ 8:00am Eastern Time – JERUSALEM–(BUSINESS ...

Teva Moves Pipeline Assets from Process to Product

mia.burns By Mia Burns (mia.burns@ubm.com) Teva executives say that developing new pipeline assets through the New Therapeutic Entities, or NTE process is a major element in the company’s ...

Relax, PCSK9ers: FDA won’t roadblock blockbusters from Sanofi, Amgen

Damian Garde On the heels of new guidelines casting doubts on a much-hyped new class of cholesterol drugs, the FDA said it would not demand long and costly outcomes trials before approving ...
Page 4 of 14« First...23456...10...Last »
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS